Skip to main content

IU researchers team up to create multicellular human models to study genetic and environmental factors in ALS and Parkinson’s disease

two researchers in white coats work near a hood in a laboratory

ALS researchers work in the Pierchala lab at Stark Neurosciences Research Institute. | Photo by Tim Yates, IU School of Medicine

Indiana University School of Medicine experts in neurodegeneration, stem cell biology and data science are collaborating to build next-generation human stem-cell based models focused on better understanding gene-environment interactions in Parkinson’s disease and ALS.

The three-year, $2 million study, funded through the school’s Targeted Research Initiative, is led by IU School of Medicine investigators Malu Tansey, PhD, Jason Meyer, PhD, and Brian Pierchala, PhD. This award will fund the development of multicellular models of Parkinson’s disease and ALS — as well as a “digital twin” of the findings using AI and machine learning. Tansey, Meyer and Pierchala are all primary members of Stark Neurosciences Research Institute; Pierchala serves as the executive associate director of the research institute.

“This award presents an opportunity to move the needle forward and bolster research across more neurodegenerative disorders, leveraging the existing strengths in ALS and Parkinson's disease,” said Meyer, the A. Donald Merritt Professor of Medical and Molecular Genetics.

The Targeted Research Initiative is a new research program sponsored by the IU School of Medicine and supported through funds provided by IU Health. The program is designed to build shared research platforms, catalyze collaboration and team science, and invest in high-potential areas that can grow into sustainable research programs positioned for larger external funding opportunities, said Tatiana Foroud, PhD, executive associate dean for research affairs.

a portrait of Jason Meyer“This is a very successful team of researchers who each brought unique expertise to the project,” Foroud said. “A strength of the proposal was that it leveraged their successful research programs to build new platforms that could develop innovative approaches to address two devastating diseases: ALS and Parkinson’s disease.”

Pierchala, the Sherry Sonneborn Professor of ALS Research, leads a lab that uses human stem cell cultures and mouse models to study how motoneurons change as ALS progresses. His team also studies environmental factors that might increase the risk of developing ALS.

Tansey, the James A. Caplin M.D. Professor of Alzheimer’s Research, and her research team investigate the role of inflammation and immune system responses on brain health and the development of neurodegenerative disorders, with a specific focus on the gut-brain connection and crosstalk between the brain and other parts of the body.

Meyer’s lab specializes in the development of human pluripotent stem cell-based models — which can be developed into any type of cell in the body — to study the central nervous system and neurological disorders, such as glaucoma and Alzheimer’s disease. He also leads one of only two centers in the United States dedicated to developing stem-cell-based models of the human brain to study the underlying causes of Alzheimer’s disease and related dementias.

"I'm not sure any of us would be able to do this on our own," Pierchala said. "This group really does bring together skills that I think are going to be very synergistic."

a portrait of Malu TanseyAn estimated 1.1 million people in the United States have Parkinson’s disease, according to the Parkinson’s Foundation, and nearly 90,000 people are newly diagnosed each year. ALS, also known as Lou Gehrig’s disease, affects close to 35,000 people in the U.S., and there are nearly 6,000 new cases each year, according to the Centers for Disease Control and Prevention.

The research team will develop multicellular models that resemble a “neighborhood” of cell types relevant to studying neurodegeneration in ALS and Parkinson’s disease, like neurons, immune cells and glial cells, Tansey said. They’ll also expose the models to environmental toxicants that are commonly associated with Parkinson’s disease and ALS to understand the cellular mechanisms affected by these exposures.

"This neighborhood approach is something that people really haven't considered much in depth” Tansey said. “They’ve started with neurons, like motor neurons in ALS and dopaminergic neurons in Parkinson's disease. But these cells don't die or live in isolation. We’re trying to assemble this multicellular culture system and validate it in a way that we show that while the individual cells are differentially vulnerable to specific exposures, together the entire neighborhood is uniquely vulnerable to environmental factors.”

Decades of scientific and environmental studies have shown that toxicants such as pesticides, herbicides, heavy metals and industrial toxins may have a significant impact on people developing ALS and Parkinson’s disease, Pierchala said. This is especially relevant in rural areas of Indiana where these environmental triggers pose a serious public health issue.

a portrait of brian pierchala

Exposing the models to these toxicants will allow the team to investigate how that exposure might lead to neurodegeneration.

“Then we're going to take some of the most well-known available treatments and see if we can suppress that degeneration,” Pierchala said. “We are really trying to think of this as a novel platform to test candidate agents and find effective drugs to suppress those effects.”

The team will collaborate with Timothy Richardson, PhD, research professor of medicine, and Travis Johnson, PhD, the Agnes Beaudry Investigator in Myeloma Research, to compare results of the models with data from large studies of patients with ALS and Parkinson’s disease.

Richardson and Johnson will work alongside their colleagues at the Indiana Biosciences Research Institute (IBRI), a nonprofit translational research institute in Indianapolis, to develop a “digital twin” of the data by using AI and machine learning to look for shared patterns and determine how well the models reflect what happens in patients.

“We hope to build a model training and prediction infrastructure to study things like disease trajectory, environmental vulnerabilities, high-risk subpopulations of patients and biomarkers for efficacy tracking and prognosis,” Johnson said. “We anticipate that by the end of this award we will have a multiomic digital twin that can be used to make prospective predictions about patients.”

Tansey said the award has provided the team of researchers a rare opportunity to build upon the existing strengths in neurodegenerative disorders research at the school and develop a “high risk, high reward” investigation that may lead to larger studies and grant programs.

“IU is making the investment in us,” Tansey said, “because they feel that if we can develop this model, validate it and apply machine learning with the data we generate to predict outcomes that we can then test experimentally and re-iterate, we will be uniquely positioned to apply for new funding opportunities where we could screen for new and more effective drugs to prevent, delay, or possibly reverse neurodegeneration.”

Default Author Avatar IUSM Logo
Author

Ben Middelkamp

Ben Middelkamp is the communications manager for Stark Neurosciences Research Institute at Indiana University School of Medicine. Before joining the Office of Strategic Communications in December 2019, Ben spent nearly six years as a newspaper reporter in two Indiana cities. He earned a bachelor’s degree in Convergent Journalism from Indiana Wesleyan University in 2014. Ben enjoys translating his background in journalism to the communications and marketing needs of the school and its physicians and researchers.

The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.